Oral Estrogen Receptor Degraders Compared to Standard Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Systematic Review and Meta-Analysis

June 26, 2026CancersOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

Evaluate the efficacy of oral estrogen receptor degraders compared to standard endocrine therapy in patients with metastatic breast cancer.
Systematic review and meta-analysis of randomized controlled trials
Intention-to-treat analysis for progression-free survival and overall survival outcomes
Subgroup analysis based on ESR1 mutation status
ER degraders improved overall survival compared to standard endocrine therapy (HR 0.81, 95% CI 0.69–0.95, p = 0.01)
Significant overall survival improvement for patients with ESR1 mutations (HR 0.70, 95% CI 0.56–0.88, p = 0.002)
ER degraders also improved progression-free survival (HR 0.81, 95% CI 0.68–0.96, p = 0.02)

We only have this paper's title and publication details.

Study compare survival outcomes in metastatic breast cancer, suggesting benefits for specific mutations.

No takes yet. Share an insight, caveat, or question.

Goldvaser et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share